Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of HP-6050 in healthy adults and elderly
jRCT2031220536Phase 1Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HP-6050 (2 arms), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoints: Pharmacokinetic parameters and Adverse events. Started Jan 2023; status: completed.
02
Drugs
HP-6050
Beyond the preview
Go deeper on jRCT2031220536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220536.